Equity
€34,582 from €270,842 in 2024
Equity fell by 87% in 1 year.
Levexia
Lifetime
4 annual accounts with figures on one time axispeak €158,402 (2024)
€156,267▼ 1.3%
peak €124,693 (2024)
€122,580▼ 1.7%
peak €270,842 (2024)
€34,582▼ 87.2%
€323,378▲ 19×
Board1 name since 2022
1 director
Documentsfilings and deeds
31-03-2026122 days before the deadline
2025micro format
Dividend €358,840Equity from €270,842 to €34,582Debts from €17,188 to €323,378Investments €2,737Cash from €26,302 to €332,188
Key points
from the 2025 annual accountsTurnover
≈ €290,000 estimated
The micro format states no turnover.
Debts
€323,378 90% of the balance sheet
Suppliers 0%Taxes and wages 0%Other 100%
Investments
€2,737 2.1 × depreciation
Green is investment, beige is depreciation. Machinery stands 120.8% higher than in 2024.
Liquidity
1.10 was 16.69 in 2024
Short-term debts rose from €17,188 to €323,378.
Position in the sector
9.7%
Lower solvency than 86% of companies in human health. Sector median 63.1% · 21,322 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 2,156 companies had the same profile as Levexia has now. Each dot stands for 6 companies, two years later.
94.1%
were still trading
2.8%
stopped another way
3.0%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,156 companies, not a prediction for Levexia. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0782893334
Incorporation
Founding capital of €2,000, 100 shares · Founder: (oprichter comparant) · Appointment: (director) · published on 08-03-2022 · Gazette deed
First establishment
Floraliënlaan 352, Antwerp
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Levexia Antwerp | €357,960 | €156,267 | 9.7% | - |
| Dokter Kortleven Ineke, anesthesie Ranst | €332,971 | €156,610 | 83.4% | - |
| Dokter Hannelore Celen Grobbendonk | €354,280 | €176,571 | 86.1% | - |
| AnGeo Wijnegem | €327,231 | €176,474 | 73.5% | - |
| Dr. E. de Bliek Cardiologie Antwerp | €327,214 | €176,192 | 86.9% | - |
| Anesthésie Zuzana Javorcikova Woluwe-Saint-Lambert | €342,341 | €163,346 | 1.2% | - |
| Annaert Anesthesie & IZ Dendermonde | €327,825 | €162,101 | 38.6% | - |
These companies have the same main activity as Levexia: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €327,000 and €354,000, founded between 2021 and 2022.
Official details
Source: KBO- Status
- Active since 04-03-2022Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.328.755.4122600 Antwerp, since 04-03-2022
- Financial year end
- 31 December
- Peppol
- Reachable since 09-09-2025
Annual accounts 2025
- €357,960▲ 24.3%
- Filing
- Filed on 31-03-2026, 122 days before the end of the filing period
Insights on Levexia
Levexia files the micro format. That format states no turnover. The gross margin rose from €48,204 in 2022 to €156,267 in 2025.
In March 2022, the Official Gazette published the appointment of as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Levexia
- What is the company number of Levexia?
- The company number of Levexia is 0782.893.334. The VAT number is the same number with BE in front: BE 0782.893.334.
- Where is Levexia based?
- The registered office is at Floraliënlaan 352, 2600 Antwerp.Company details
- What does Levexia do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of Levexia?
- Levexia is a private limited company (BV).
- When was Levexia founded?
- Levexia was founded on 04-03-2022.
- Is Levexia still active?
- Yes, Levexia is an active enterprise in the KBO register.
- What is the turnover of Levexia?
- The turnover in financial year 2025 is ≈ €290,000. This figure is estimated from the gross margin of €156,267 and 40 comparable companies (NACE 86220). It probably lies between €250,000 and €390,000.Financials
- Is Levexia profitable?
- In financial year 2025, Levexia made a profit of €122,580.
- Where can I find the annual accounts of Levexia?
- Levexia filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Levexia due?
- Levexia must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.